NANO MRNALtd Gestione

Gestione criteri di controllo 1/4

NANO MRNALtd Il CEO è Shiro Akinaga, nominato in Dec2022, ha un mandato di 1.92 anni. possiede direttamente 0.29% delle azioni della società, per un valore di € 218.96K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 4.4 anni.

Informazioni chiave

Shiro Akinaga

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.9yrs
Proprietà del CEO	0.3%
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	4.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Shiro Akinaga (68 yo)

1.9yrs

Mandato

Dr. Shiro Akinaga, Ph.D. serves as Director at NANO MRNA Co.,Ltd. (formerly known as NanoCarrier Co., Ltd.) since June 2020 and serves as its President and Chief Executive Officer since December 2022. Dr....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Atsushi Matsumura	Executive Chairman of the Board	12.7yrs	Nessun dato	Nessun dato
Shiro Akinaga	President	1.9yrs	Nessun dato	0.29% € 219.0k
Koji Fujimoto	CFO, MD of Corporate Division & Director	1.4yrs	Nessun dato	0.051% € 38.2k

1.8yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di 3NQ non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Atsushi Matsumura	Executive Chairman of the Board	12.7yrs	Nessun dato	Nessun dato
Shiro Akinaga	President	4.4yrs	Nessun dato	0.29% € 219.0k
Koji Fujimoto	CFO, MD of Corporate Division & Director	4.4yrs	Nessun dato	0.051% € 38.2k
Satoru Iino	Independent Director	12.7yrs	Nessun dato	Nessun dato
Teruo Okano	Independent External Director	28.4yrs	Nessun dato	0.46% € 342.2k
Takashi Matsuo	Outside Audit & Supervisory Board Member	1.4yrs	Nessun dato	Nessun dato
Tetsuhito Matsuyama	Chairman of Standing Audit & Supervisory Board	1.4yrs	Nessun dato	0.19% € 143.3k
Kazunori Kataoka	Independent Director	4.4yrs	Nessun dato	0.46% € 342.8k
Yuki Hasegawa	Independent Director	3.4yrs	Nessun dato	Nessun dato
Seiichiro Wada	Outside Audit & Supervisory Board Member	1.4yrs	Nessun dato	Nessun dato

4.4yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 3NQ sono considerati esperti (durata media dell'incarico 4.4 anni).

NANO MRNALtd Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NANO MRNA Co.,Ltd., Annual General Meeting, Jun 27, 2024

NanoCarrier Co., Ltd., Annual General Meeting, Jun 29, 2023

NanoCarrier Co., Ltd., Annual General Meeting, Jun 27, 2022

Recent updates

NANO MRNA Co.,Ltd. to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: JP¥2.22 loss per share (vs JP¥2.73 loss in 1Q 2024)

NANO MRNA Co.,Ltd. to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: JP¥11.10 loss per share (vs JP¥18.69 loss in FY 2023)

NANO MRNA Co.,Ltd., Annual General Meeting, Jun 27, 2024

New major risk - Share price stability

NANO MRNA Co.,Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

NANO MRNA Co.,Ltd. to Report Q3, 2024 Results on Feb 14, 2024

NANO MRNA Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

New minor risk - Market cap size

NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.

NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.

NanoCarrier Co., Ltd., Annual General Meeting, Jun 29, 2023

Third quarter 2023 earnings released: JP¥1.60 loss per share (vs JP¥6.24 loss in 3Q 2022)

NanoCarrier Co., Ltd. announced that it has received KRW 1.11096909 billion in funding from Whiz Partners Inc.

NanoCarrier Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: JP¥7.99 loss per share (vs JP¥7.31 loss in 2Q 2022)

Second quarter 2023 earnings released: JP¥7.99 loss per share (vs JP¥7.31 loss in 2Q 2022)

NanoCarrier Co., Ltd. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥4.67 loss per share (vs JP¥6.64 loss in 1Q 2022)

NanoCarrier Co., Ltd. to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: JP¥26.89 loss per share (vs JP¥41.52 loss in FY 2021)

NanoCarrier Co., Ltd., Annual General Meeting, Jun 27, 2022

NanoCarrier Co., Ltd. to Report Fiscal Year 2022 Results on May 12, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥7.31 loss per share (vs JP¥27.69 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥6.64 loss per share (vs JP¥3.30 loss in 1Q 2021)

NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer

Full year 2021 earnings released: JP¥41.52 loss per share (vs JP¥32.67 loss in FY 2020)

Third quarter 2021 earnings released: JP¥5.27 loss per share (vs JP¥3.65 loss in 3Q 2020)

New 90-day low: €2.32

New 90-day low: €2.76

NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer

Second quarter 2021 earnings released: JP¥27.69 loss per share

Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer

NanoCarrier Co., Ltd. to Report Q2, 2021 Results on Nov 12, 2020

New 90-day low - €2.86

First quarter earnings released

NanoCarrier Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media